Estraderm and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

There is some concern that estradiol and other estrogen-containing products may increase the risk of liver problems associated with the use of paritaprevir. Data are limited. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Theoretical concerns exist that coadministration of estrogen-containing products may increase the risk of liver enzyme elevations associated with the use of ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. The proposed mechanism is the inhibition of UDP-glucuronosyltransferase (UGT) by ombitasvir, paritaprevir, and dasabuvir. During clinical trials, approximately 1% of all subjects experienced post-baseline serum ALT levels greater than 5 times the upper limit of normal (ULN) after starting treatment, with or without ribavirin. The incidence increased to 25% (4/16) among women taking a concomitant medication containing ethinyl estradiol. Although the incidence of clinically relevant ALT elevations among women using estrogens other than ethinyl estradiol, such as estradiol and conjugated estrogens used in hormone replacement therapy, was just 3% (2/59), a similarly increased risk cannot be ruled out due to the limited number of subjects taking these other estrogens. In general, ALT elevations were asymptomatic, occurred during the first 4 weeks of treatment (mean 20 days; range 8 to 57 days), and declined within two to eight weeks of onset despite continued therapy. Elevations in ALT were typically not associated with bilirubin elevations, and cirrhosis was not a risk factor.

MANAGEMENT: Caution is recommended if estrogen-containing products are used in patients receiving ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. Liver function tests should be performed on all patients during the first 4 weeks of treatment and as clinically indicated thereafter. If ALT is elevated above baseline at any time during treatment, the test should be repeated and monitored closely. Therapy should be discontinued if ALT levels remain persistently greater than 10 times the ULN, or if ALT elevations are accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.

Estraderm

Generic Name: estradiol

Brand name: Estraderm, Vivelle, Alora, Climara, Estradiol Patch, Menostar, Minivelle, Vivelle-Dot, Delestrogen, Depo-Estradiol, Divigel, Elestrin Pump, Estrasorb, EstroGel Pump, Evamist, Estrace, DepoEstradiol, Elestrin, Estradot, Estrogel, Femtrace, Femring, Gynodiol

Synonyms: n.a.

What is Estraderm?

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets

Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir

Brand name: Viekira XR, Viekira Pak

Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets, and Dasabuvir

What is Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets?